# Semaglutide

Semaglutide is FDA-approved as Ozempic, Wegovy and Rybelsus, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.

Status checked: 2026-10-24. Last verified: 2026-10-25. Primary source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

This page has not been individually reviewed by a clinician.

Information, not medical advice.

| Fact | Value | Tier | Checked | Source |
|---|---|---|---|---|
| Also called | Ozempic, Wegovy, Rybelsus | primary | 2026-10-24 | [source](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) |
| Class | glp-1-agonist | primary | 2026-10-24 | [source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) |
| Regulatory status | fda-approved | primary | 2026-10-24 | [source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256) |
| Status source read | 2026-10-23 | primary | 2026-10-24 | [source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637) |
| Evidence grade | strong-human | our assessment | 2026-10-24 | [source](https://peptideindex.ai/methodology#evidence-grade) |
| Label dosing | From the Wegovy label. Wegovy shot: once a week, starting at 0.25 mg for 4 weeks and going up every 4 weeks. The usual dose to stay on is 2.4 mg a week, and some adults may go up to 7.2 mg. Wegovy pill: once a day on an empty stomach, starting at 1.5 mg for 30 days and going up every 30 days to 25 mg. Ozempic and Rybelsus have their own schedules on their labels. The prescriber sets the dose. | primary | 2026-10-24 | [source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) |

## Name

Semaglutide

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

## Summary

A prescription drug that copies the gut hormone GLP-1. FDA approved it as Ozempic, Wegovy and Rybelsus for diabetes, weight loss and heart risk.

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

## Short answer

Semaglutide is FDA-approved as Ozempic, Wegovy and Rybelsus, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.

Source: https://peptideindex.ai/methodology#short-answer

## Known risks

- In rats and mice, semaglutide caused thyroid tumors. The labels warn people with a rare thyroid cancer in the family not to use it [^4] [^5].
- The most common problems are nausea, vomiting, diarrhea, belly pain and constipation [^4]. More people on it than on a dummy shot quit for stomach trouble [^19].
- The labels warn of a swollen pancreas and gallbladder disease. They also warn of kidney harm from losing fluids, and of bad allergic reactions [^4] [^5].
- Taken with insulin or some other diabetes drugs, it can push blood sugar too low [^4].
- In a diabetes trial, eye damage from diabetes got worse more often in people on semaglutide [^18].
- FDA has reports of people who took 5 to 20 times the intended amount of compounded semaglutide. Some went to the hospital [^12].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

## What nobody knows yet

- Nobody knows if it can cause thyroid cancer in people. The rat and mouse studies do not tell us [^4].
- A 2025 review linked it to a rare eye nerve problem that can take away sight. The evidence is too thin to say it is the cause [^22].
- The main weight trial lasted 68 weeks, so it does not show what years of use do [^19].
- Nobody knows if the salt forms some pharmacies use act like the approved drug [^10].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

## What it is

Semaglutide is a prescription drug. It copies GLP-1, a hormone the gut makes after you eat [^4]. GLP-1 helps control blood sugar and makes you feel full. FDA first approved it in 2017 [^4]. One company makes it and sells it under three brand names [^1] [^2] [^3].

Ozempic is a weekly shot for type 2 diabetes. It now also comes as a daily pill [^3] [^4]. Wegovy is a weekly shot or a daily pill for weight loss and heart health [^5]. Rybelsus is a daily pill for type 2 diabetes [^6]. The body clears half of a dose in about a week [^4]. That is why the shots are taken once a week.

Some pharmacies and online sellers offer their own copies of it. Those copies are not the approved drug [^10].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

## Where it stands legally

Semaglutide is FDA-approved: FDA first approved it in 2017, and it is sold as Ozempic, Wegovy and Rybelsus [^1] [^2] [^3] [^4]. That covers the brand drugs, with a prescription, for the uses on their labels. It does not make copies from pharmacies or online sellers approved [^10]. Checked 23 October 2026.

Ozempic is approved for type 2 diabetes, not for weight loss. Wegovy is the brand approved for weight loss [^4] [^5]. Many copies are sold for weight loss [^12].

The shots were on FDA's drug shortage list until 2025 [^7] [^8]. During a shortage, pharmacies may make copies of a drug. FDA said the shortage was over on 21 February 2025 [^7] [^8]. Pharmacies had until 22 April 2025 to stop making copies. Larger outsourcing facilities had until 22 May 2025 [^9] [^16]. A court refused to block this in April 2025 [^9].

Today a pharmacy may not make copies of the approved drug as a regular practice [^9]. It may make a different version for one patient. The prescriber has to write down why that patient needs the change [^16] [^17]. FDA says it will not act on four or fewer copy prescriptions a month [^9]. In April 2026, FDA proposed a rule to keep outsourcing facilities from making it from raw powder. The rule is not final [^14] [^17]. Selling it with a research-use label is illegal [^15].

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637

## What the evidence shows

The evidence grade is strong-human: several large trials in people agree that it lowers blood sugar, weight and heart risk [^18] [^19] [^20]. In a two-year trial of 3,297 adults with type 2 diabetes, fewer people on it had a heart attack, a stroke or a heart death than people on a dummy shot [^18]. In a 68-week trial of 1,961 adults with obesity and no diabetes, people on it lost about 15% of their weight. People on the dummy shot lost about 2% [^19]. In a trial of 17,604 adults with heart disease and excess weight but no diabetes, it cut heart attacks, strokes and heart deaths by about a fifth [^20]. A 2024 review of 38 studies found fewer hospital stays for heart failure and fewer deaths. It also found more stomach trouble [^21].

These trials tested the approved drug from its maker, and the maker paid for them [^18] [^19] [^20]. They tell us nothing about copies made by pharmacies or sold for research use. FDA has not checked those copies for quality [^10].

Source: https://pubmed.ncbi.nlm.nih.gov/33567185/

## Legitimate ways to get it

The legal way to get semaglutide is a prescription for one of the approved brands, filled at a state-licensed pharmacy [^1] [^10]. Ozempic, Wegovy and Rybelsus are each approved by FDA [^1] [^2] [^3]. Each label says who it is for and how it is taken [^4] [^5] [^6].

A copy made by a pharmacy is lawful only in narrow cases. The prescriber has to write down why one patient needs a change from the approved drug, such as an allergy to one of its parts [^16] [^17]. A lower price or a wish for a different form is not enough [^17]. FDA says pharmacy copies should be used only when an approved drug cannot meet a patient's needs [^10]. FDA does not check pharmacy copies for safety, quality or whether they work [^10].

Open trials are listed in the trials block below, with the date the official registry was last checked.

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637

## How people are getting it anyway

This section describes what happens and is not a recommendation.

Semaglutide reaches people outside the approved brands in four main ways [^10]. The first is pharmacies that kept making copies after the shortage ended [^9] [^13]. FDA has received reports of harm tied to pharmacy copies and says many more likely go unreported [^10]. The second is online prescribers that sell these copies. FDA has told companies they may not call a copy generic or the same as the approved drug [^13]. The third is fake Ozempic pens. FDA has seized fake pens from the US drug supply three times since 2023 [^11]. The fourth is online sellers that label it for research use. FDA has warned such a seller that the label does not make the sale legal [^15].

In each case, FDA cannot vouch for what is in the product [^10]. Some pharmacy copies use salt forms, which are a different ingredient from the approved drug [^10] [^12]. Some carry the name of a pharmacy that does not exist or did not make them [^10]. People have taken many times the intended amount by mistake [^12].

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

## Access routes

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637

### Approved product

Detail: Approved by FDA and sold with a prescription as weekly shots and daily pills. Ozempic and Rybelsus are for type 2 diabetes. Wegovy is for weight loss and heart risk.

Brand names: Ozempic, Wegovy, Rybelsus

Manufacturer: Novo Nordisk

Indication: Type 2 diabetes, and lower heart and kidney risk in some adults with it (Ozempic, Rybelsus). Weight loss, lower heart risk, and a fatty liver disease called MASH (Wegovy).

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637

### Lawful compounding

Detail: FDA said the shortage ended on 21 February 2025. A pharmacy may make a version for one patient only when the prescriber writes down why that patient needs a change from the approved drug. Regular copies of the approved drug are not allowed.

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

## Unofficial channels

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

### Compounding outside the rules

What it is: Copies of the approved shots made by pharmacies and outsourcing facilities, often sent in vials that hold several doses.

Legal position: Since the shortage ended in 2025, a pharmacy may not make copies of the approved drug as a regular practice. FDA knows of no lawful basis for making it from salt forms such as semaglutide sodium. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

Documented risks:

- FDA has reports of people who took 5 to 20 times the intended amount from multi-dose vials. Some went to the hospital with vomiting, fainting, a swollen pancreas or gallstones. (source: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded)
- FDA has received reports of harm tied to compounded semaglutide and says many more likely go unreported. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
- FDA has found fake compounded semaglutide with labels naming pharmacies that do not exist or did not make it. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

Enforcement:

- 2026-02-06: FDA said it would restrict the raw ingredient used for mass-marketed copies, and warned that seizure and court orders may follow. (source: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs)
- 2026-04-30: FDA proposed keeping semaglutide off the list of bulk ingredients outsourcing facilities may use. The proposal is not final. (source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list)

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

### Telehealth

What it is: Online prescribers that sell compounded semaglutide after a short online visit, often by monthly plan.

Legal position: FDA says a company may not claim a compounded copy is a generic, is the same as the approved drug, or is proven to work. (source: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs)

Documented risks:

- FDA reviewed a case where a patient could not get clear instructions from an online prescriber and took five times the intended amount. (source: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded)
- FDA has complaints that compounded GLP-1 drugs arrived warm, which can harm their quality. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

Enforcement:

- 2026-02-06: FDA said it would act against misleading marketing of compounded GLP-1 drugs, after warning letters sent in the fall of 2025. (source: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs)

Source: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs

### Counterfeit or diverted

What it is: Fake Ozempic pens sold outside the maker's own supply chain. Some reached the regular US drug supply.

Legal position: Counterfeit drugs are illegal, FDA says. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

Documented risks:

- A fake drug may hold the wrong ingredient, too much or too little drug, or none at all, FDA warns. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
- In fake pens seized in 2023, the needles were also fake, so nobody could confirm they were germ-free. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain)

Enforcement:

- 2023-12-21: FDA said it had seized thousands of fake Ozempic pens from the US drug supply. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain)
- 2025-04-14: FDA said it had seized several hundred fake Ozempic pens on 9 April 2025. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain)
- 2025-12-05: FDA said it had found more fake Ozempic pens in the US drug supply. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain)

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

### Research use seller

What it is: Sold online as a powder with a label saying it is for research use or not for people.

Legal position: FDA treats these as unapproved new drugs when the seller's site shows they are meant for people, whatever the label says. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026)

Documented risks:

- FDA says these products are of unknown quality and may harm health. (source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
- FDA warns that injected products skip some of the body's defenses, so toxins or germs in them can cause life-threatening illness. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026)

Enforcement:

- 2026-08-24: FDA warning letter to an online seller of research-use peptides, including semaglutide. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026)

Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026

## Recruiting trials

Snapshot date: 2026-10-25.

A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record.

- nct NCT07586150, url https://clinicaltrials.gov/study/NCT07586150, phase Not applicable, title Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN), status not-yet-recruiting, sponsor Ludwig-Maximilians - University of Munich, countries Austria, Germany, Netherlands, us states none listed
- nct NCT07430332, url https://clinicaltrials.gov/study/NCT07430332, phase Phase 2, title GLP-1 RA for Stage 1 Type 1 Diabetes, status not-yet-recruiting, sponsor Children's Hospital Medical Center, Cincinnati, countries United States, us states Ohio
- nct NCT07797036, url https://clinicaltrials.gov/study/NCT07797036, phase Phase 2/Phase 3, title Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus, status not-yet-recruiting, sponsor University of Massachusetts, Worcester, countries United States, us states Massachusetts
- nct NCT07711548, url https://clinicaltrials.gov/study/NCT07711548, phase Not applicable, title Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?, status not-yet-recruiting, sponsor Knut Mai, countries none listed, us states none listed
- nct NCT07754045, url https://clinicaltrials.gov/study/NCT07754045, phase Phase 2, title Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults, status not-yet-recruiting, sponsor Lumos Pharma, countries none listed, us states none listed
- nct NCT07731256, url https://clinicaltrials.gov/study/NCT07731256, phase Phase 2, title Semaglutide for Low Back Pain, status not-yet-recruiting, sponsor Washington University School of Medicine, countries United States, us states Alabama, Missouri
- nct NCT05714683, url https://clinicaltrials.gov/study/NCT05714683, phase Not stated, title Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea, status not-yet-recruiting, sponsor Novo Nordisk A/S, countries none listed, us states none listed
- nct NCT07879612, url https://clinicaltrials.gov/study/NCT07879612, phase Phase 2, title Semaglutide for the Treatment of Cannabis Use Disorder, status not-yet-recruiting, sponsor Massachusetts General Hospital, countries none listed, us states none listed
- nct NCT07462663, url https://clinicaltrials.gov/study/NCT07462663, phase Phase 4, title SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer, status not-yet-recruiting, sponsor Hospital Universitari de Bellvitge, countries none listed, us states none listed
- nct NCT07614412, url https://clinicaltrials.gov/study/NCT07614412, phase Phase 2, title SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes., status not-yet-recruiting, sponsor Ministry of Health, Saudi Arabia, countries Saudi Arabia, us states none listed
- nct NCT07820358, url https://clinicaltrials.gov/study/NCT07820358, phase Phase 2, title Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer, status not-yet-recruiting, sponsor The Methodist Hospital Research Institute, countries United States, us states Texas
- nct NCT07787936, url https://clinicaltrials.gov/study/NCT07787936, phase Not stated, title GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry, status not-yet-recruiting, sponsor Miedziowe Centrum Zdrowia SA, countries Poland, us states none listed
- nct NCT07858331, url https://clinicaltrials.gov/study/NCT07858331, phase Phase 4, title Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access, status not-yet-recruiting, sponsor Kristin Clemens, countries Canada, us states none listed
- nct NCT07760948, url https://clinicaltrials.gov/study/NCT07760948, phase Phase 2, title HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide, status not-yet-recruiting, sponsor Vanderbilt University Medical Center, countries United States, us states Tennessee
- nct NCT07770282, url https://clinicaltrials.gov/study/NCT07770282, phase Phase 3, title Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome, status not-yet-recruiting, sponsor All India Institute of Medical Sciences, Bhubaneswar, countries none listed, us states none listed
- nct NCT06977438, url https://clinicaltrials.gov/study/NCT06977438, phase Phase 4, title GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward, status not-yet-recruiting, sponsor University of Minnesota, countries United States, us states Minnesota
- nct NCT07855900, url https://clinicaltrials.gov/study/NCT07855900, phase Phase 3, title SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight, status not-yet-recruiting, sponsor Boehringer Ingelheim, countries United States, us states Florida
- nct NCT07866066, url https://clinicaltrials.gov/study/NCT07866066, phase Phase 3, title Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes, status not-yet-recruiting, sponsor Amgen, countries none listed, us states none listed
- nct NCT07249554, url https://clinicaltrials.gov/study/NCT07249554, phase Phase 2, title Combination Therapy for Alcohol Use Disorder, status not-yet-recruiting, sponsor Johns Hopkins University, countries United States, us states Maryland
- nct NCT07878494, url https://clinicaltrials.gov/study/NCT07878494, phase Not applicable, title Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia, status not-yet-recruiting, sponsor Stanford University, countries United States, us states California
- nct NCT06546384, url https://clinicaltrials.gov/study/NCT06546384, phase Not applicable, title GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease, status not-yet-recruiting, sponsor Insel Gruppe AG, University Hospital Bern, countries Switzerland, us states none listed
- nct NCT07832084, url https://clinicaltrials.gov/study/NCT07832084, phase Phase 4, title Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s, status not-yet-recruiting, sponsor Jing Luo, countries United States, us states Pennsylvania
- nct NCT07027969, url https://clinicaltrials.gov/study/NCT07027969, phase Phase 4, title Metabolic Surgery for Atrial Fibrillation Elimination, status not-yet-recruiting, sponsor Ali Aminian, countries United States, us states Ohio
- nct NCT07845994, url https://clinicaltrials.gov/study/NCT07845994, phase Phase 3, title SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years, status not-yet-recruiting, sponsor University Hospital, Angers, countries France, us states none listed
- nct NCT07511543, url https://clinicaltrials.gov/study/NCT07511543, phase Phase 2, title Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy, status not-yet-recruiting, sponsor Population Health Research Institute, countries none listed, us states none listed
- nct NCT07881783, url https://clinicaltrials.gov/study/NCT07881783, phase Not stated, title A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy, status not-yet-recruiting, sponsor Novartis Pharmaceuticals, countries none listed, us states none listed
- nct NCT07840729, url https://clinicaltrials.gov/study/NCT07840729, phase Phase 1, title Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants, status not-yet-recruiting, sponsor Shanghai JMT-Bio Inc., countries China, us states none listed
- nct NCT07874971, url https://clinicaltrials.gov/study/NCT07874971, phase Not applicable, title Short Term Effects of Semaglutide on Body Composition and Performance, status not-yet-recruiting, sponsor Morten Hostrup, PhD, countries Denmark, us states none listed
- nct NCT07874932, url https://clinicaltrials.gov/study/NCT07874932, phase Not applicable, title Long-Term Effects of Semaglutide on Body Composition and Performance in Running, status not-yet-recruiting, sponsor Morten Hostrup, PhD, countries Denmark, us states none listed
- nct NCT07891156, url https://clinicaltrials.gov/study/NCT07891156, phase Phase 2/Phase 3, title Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity., status recruiting, sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre, countries Canada, us states none listed
- nct NCT07881770, url https://clinicaltrials.gov/study/NCT07881770, phase Not stated, title Semaglutide Health Outcomes and Patient Adherence in Australia, status not-yet-recruiting, sponsor Novo Nordisk A/S, countries Australia, us states none listed
- nct NCT07812597, url https://clinicaltrials.gov/study/NCT07812597, phase Phase 2, title A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ), status not-yet-recruiting, sponsor Beijing QL Biopharmaceutical Co.,Ltd, countries China, us states none listed
- nct NCT07627191, url https://clinicaltrials.gov/study/NCT07627191, phase Early phase 1, title GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer, status recruiting, sponsor University of Arizona, countries United States, us states Arizona
- nct NCT07855133, url https://clinicaltrials.gov/study/NCT07855133, phase Phase 1, title A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication, status recruiting, sponsor Novo Nordisk A/S, countries United States, us states California, Maryland
- nct NCT07816744, url https://clinicaltrials.gov/study/NCT07816744, phase Not applicable, title Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression, status not-yet-recruiting, sponsor Axel Brandes, countries Denmark, us states none listed
- nct NCT07859137, url https://clinicaltrials.gov/study/NCT07859137, phase Phase 4, title Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher, status not-yet-recruiting, sponsor General Committee of Teaching Hospitals and Institutes, Egypt, countries Egypt, us states none listed
- nct NCT07423481, url https://clinicaltrials.gov/study/NCT07423481, phase Not stated, title Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity, status not-yet-recruiting, sponsor Nantes University Hospital, countries France, us states none listed
- nct NCT07859150, url https://clinicaltrials.gov/study/NCT07859150, phase Phase 4, title Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE), status not-yet-recruiting, sponsor General Committee of Teaching Hospitals and Institutes, Egypt, countries Egypt, us states none listed
- nct NCT07872904, url https://clinicaltrials.gov/study/NCT07872904, phase Phase 4, title FutureShape Family, status not-yet-recruiting, sponsor Signe Torekov, countries Denmark, us states none listed
- nct NCT07859189, url https://clinicaltrials.gov/study/NCT07859189, phase Phase 4, title Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery, status not-yet-recruiting, sponsor General Committee of Teaching Hospitals and Institutes, Egypt, countries Egypt, us states none listed
- nct NCT07389941, url https://clinicaltrials.gov/study/NCT07389941, phase Phase 4, title Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation, status not-yet-recruiting, sponsor University of Luebeck, countries none listed, us states none listed
- nct NCT07737522, url https://clinicaltrials.gov/study/NCT07737522, phase Phase 2, title Myocardial Metabolic Flux in Pulmonary Arterial Hypertension, status not-yet-recruiting, sponsor Imperial College London, countries none listed, us states none listed
- nct NCT07859176, url https://clinicaltrials.gov/study/NCT07859176, phase Phase 4, title Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery, status not-yet-recruiting, sponsor General Committee of Teaching Hospitals and Institutes, Egypt, countries Egypt, us states none listed
- nct NCT07755085, url https://clinicaltrials.gov/study/NCT07755085, phase Phase 4, title GLP-1s in Hip and Knee Arthroplasty, status not-yet-recruiting, sponsor Nova Scotia Health Authority, countries Canada, us states none listed
- nct NCT07820722, url https://clinicaltrials.gov/study/NCT07820722, phase Early phase 1, title Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI, status not-yet-recruiting, sponsor Sunnybrook Health Sciences Centre, countries none listed, us states none listed
- nct NCT07772960, url https://clinicaltrials.gov/study/NCT07772960, phase Phase 1, title Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes, status not-yet-recruiting, sponsor Yale University, countries United States, us states Connecticut
- nct NCT07859163, url https://clinicaltrials.gov/study/NCT07859163, phase Phase 4, title Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain, status not-yet-recruiting, sponsor General Committee of Teaching Hospitals and Institutes, Egypt, countries Egypt, us states none listed
- nct NCT07845500, url https://clinicaltrials.gov/study/NCT07845500, phase Phase 3, title A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity, status recruiting, sponsor Pfizer, countries United States, us states Alabama, California, Florida, Kentucky, Michigan, Mississippi, Missouri, Montana, North Carolina, Ohio, South Carolina
- nct NCT07845578, url https://clinicaltrials.gov/study/NCT07845578, phase Phase 1, title A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight, status not-yet-recruiting, sponsor Novo Nordisk A/S, countries Austria, us states none listed
- nct NCT07668414, url https://clinicaltrials.gov/study/NCT07668414, phase Phase 3, title A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide, status recruiting, sponsor Novo Nordisk A/S, countries United States, us states California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina, North Dakota, Pennsylvania, South Carolina, Texas, Virginia, Washington

Source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide+OR+Ozempic+OR+Wegovy+OR+Rybelsus&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState

## Sources

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

### 1. Drugs@FDA: Ozempic injection, application 209637

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637

### 2. Drugs@FDA: Wegovy injection, application 215256

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

### 3. Drugs@FDA: Rybelsus and Ozempic tablets, application 213051

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051

### 4. DailyMed: Ozempic injection prescribing information, revised May 2026

Type: label

Tier: primary

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

### 5. DailyMed: Wegovy injection and tablets prescribing information, revised June 2026

Type: label

Tier: primary

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

### 6. DailyMed: Rybelsus and Ozempic tablets prescribing information, revised January 2026

Type: label

Tier: primary

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98

### 7. FDA drug shortages: semaglutide injection, resolved

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r

### 8. FDA order: the semaglutide injection shortage is resolved, 21 February 2025

Type: regulatory

Tier: primary

Source: https://www.fda.gov/media/185526/download

### 9. FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

### 10. FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

### 11. FDA: warnings on counterfeit Ozempic in the US drug supply, 2023 to 2025

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain

### 12. FDA: dosing errors with compounded semaglutide injections, 2024

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

### 13. FDA statement: action against non-approved GLP-1 drugs, 6 February 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs

### 14. FDA: proposal to exclude semaglutide from the 503B bulks list, 30 April 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

### 15. FDA warning letter to an online seller of research-use peptides, 24 August 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026

### 16. McDermott Will & Schulte: what the end of the semaglutide shortage means

Type: legal-analysis

Tier: legal-analysis

Source: https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/

### 17. Orrick: FDA moves to end large-scale compounding of GLP-1 drugs

Type: legal-analysis

Tier: legal-analysis

Source: https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs

### 18. SUSTAIN-6: semaglutide and heart outcomes in type 2 diabetes, 2016

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/27633186/

### 19. STEP 1: weekly semaglutide in adults with overweight or obesity, 2021

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/33567185/

### 20. SELECT: semaglutide and heart outcomes in obesity without diabetes, 2023

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/37952131/

### 21. Review of heart outcomes and harms of semaglutide in overweight or obesity, 2024

Type: systematic-review

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/39396098/

### 22. Review of eye disorders, including an optic nerve problem, with semaglutide, 2025

Type: systematic-review

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/40810985/

### 23. STAT: FDA proposes a rule that would end bulk compounding of GLP-1 drugs

Type: reference

Tier: established-news

Source: https://www.statnews.com/pharmalot/2026/04/30/fda-weight-loss-drugs-new-rule-would-end-glp-1-compound-pharmacy/

### 24. NBC News: FDA proposes keeping weight-loss drugs off a key compounding list

Type: reference

Tier: established-news

Source: https://www.nbcnews.com/health/health-news/fda-proposes-compounded-ozempic-zepbound-wegovy-weight-loss-telehealth-rcna342957

Last verified: 2026-10-25.

Sources:

- https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide+OR+Ozempic+OR+Wegovy+OR+Rybelsus&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://peptideindex.ai/methodology#evidence-grade
- https://peptideindex.ai/methodology#short-answer
- https://pubmed.ncbi.nlm.nih.gov/33567185/
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

[^1]: Drugs@FDA: Ozempic injection, application 209637 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
[^2]: Drugs@FDA: Wegovy injection, application 215256 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
[^3]: Drugs@FDA: Rybelsus and Ozempic tablets, application 213051 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
[^4]: DailyMed: Ozempic injection prescribing information, revised May 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
[^5]: DailyMed: Wegovy injection and tablets prescribing information, revised June 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[^6]: DailyMed: Rybelsus and Ozempic tablets prescribing information, revised January 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
[^7]: FDA drug shortages: semaglutide injection, resolved https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r
[^8]: FDA order: the semaglutide injection shortage is resolved, 21 February 2025 https://www.fda.gov/media/185526/download
[^9]: FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026 https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
[^10]: FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026 https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[^11]: FDA: warnings on counterfeit Ozempic in the US drug supply, 2023 to 2025 https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain
[^12]: FDA: dosing errors with compounded semaglutide injections, 2024 https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
[^13]: FDA statement: action against non-approved GLP-1 drugs, 6 February 2026 https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
[^14]: FDA: proposal to exclude semaglutide from the 503B bulks list, 30 April 2026 https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
[^15]: FDA warning letter to an online seller of research-use peptides, 24 August 2026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026
[^16]: McDermott Will & Schulte: what the end of the semaglutide shortage means https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/
[^17]: Orrick: FDA moves to end large-scale compounding of GLP-1 drugs https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs
[^18]: SUSTAIN-6: semaglutide and heart outcomes in type 2 diabetes, 2016 https://pubmed.ncbi.nlm.nih.gov/27633186/
[^19]: STEP 1: weekly semaglutide in adults with overweight or obesity, 2021 https://pubmed.ncbi.nlm.nih.gov/33567185/
[^20]: SELECT: semaglutide and heart outcomes in obesity without diabetes, 2023 https://pubmed.ncbi.nlm.nih.gov/37952131/
[^21]: Review of heart outcomes and harms of semaglutide in overweight or obesity, 2024 https://pubmed.ncbi.nlm.nih.gov/39396098/
[^22]: Review of eye disorders, including an optic nerve problem, with semaglutide, 2025 https://pubmed.ncbi.nlm.nih.gov/40810985/